Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

Zacks' Style Scores, which rate stocks based on value, growth, and momentum (A-F), are presented as a complementary tool to the Zacks Rank for identifying potential market outperformers. AstraZeneca (AZN), a major biopharmaceutical company, is highlighted as a stock warranting investor attention, despite its Zacks #3 (Hold) Rank. This is attributed to its strong 'A' VGM Score and 'B' Value Style Score, supported by an attractive 15.56 forward P/E and recent upward revisions to its fiscal 2025 earnings estimate, now at $4.49 per share.

Analysis

AstraZeneca (AZN) presents a nuanced investment case, characterized by a neutral Zacks #3 (Hold) rank that is counterbalanced by strong underlying fundamental metrics. The company secures a top-tier 'A' for its consolidated VGM (Value, Growth, Momentum) score and a 'B' grade for its Value score, underpinned by an attractive forward P/E ratio of 15.56. This suggests the stock may be undervalued relative to its peers or its own historical levels. Positive sentiment from analysts is evident, with two upward earnings estimate revisions for fiscal 2025 in the last 60 days, establishing a consensus estimate of $4.49 per share. Furthermore, AstraZeneca's operational consistency is highlighted by a historical average earnings surprise of 4.2%, indicating a reliable pattern of exceeding market expectations. These factors collectively suggest that despite the neutral overall rank, the stock possesses solid value characteristics and a positive earnings outlook that warrants investor attention.

Key Decisions for Investors

• Value-oriented investors should consider AstraZeneca's attractive forward P/E of 15.56 and strong 'B' Value Score as a potential entry point, as these metrics suggest the stock may be trading below its intrinsic worth.
• Investors should closely monitor future analyst earnings estimate revisions, as the recent upward trend for fiscal 2025 is a primary bullish indicator that currently contrasts with the stock's neutral 'Hold' rating.
• Given the mixed signals of a neutral rank but strong value scores, the stock appears better suited for long-term portfolios rather than those seeking short-term momentum, aligning with the thesis of it being a 'Top Value Stock for the Long-Term'.